🕒 Last update: loading…

Stock NRx Pharmaceuticals, Inc. NRXP

NRx Pharmaceuticals, Inc. — Investlytic score 0/5 on the five criteria.

-
-
0/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 0/5 criteria met.

  • ❌ Price trend failed
  • ❌ Growth failed
  • ❌ Debt failed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: 3.92%

Price change 2019 → 2020: 130.19%

Price change 2020 → 2021: -80.41%

Price change 2021 → 2022: -76.78%

Price change 2022 → 2023: -58.56%

Price change 2023 → 2024: -52.17%

Price change 2024 → 2025: 23.18%

Price change 2025 → 2026: 16.24%

Price change 2026 (year to date): 20.23%

Financial growth

Revenue CAGR (8 years): N/A

Earnings CAGR (8 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 631000.00

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -7.85

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 31.82% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
NRx Pharmaceuticals, Inc.–––🔒
Onward Medical N.V.–0.25+34.5 %–
Guerbet S.A.–1.64+5.5 %–
OrganiGram Holdings Inc.2.10.03––
Euroapi S.A.–0.08−1.3 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Accounts and financial health

Balance sheet and cash flow published by NRx Pharmaceuticals, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
-13.81
risk zone (below 1.81)
Piotroski Score
4 / 9
4 to 6: average accounts
DCF Value
0.700 USD
DCF below share price · share price 2.31 USD, gap -69.8 %
Net Debt / EBITDA
1.16 x
moderate debt
Fiscal year20212022202320242025
Cash and investments27.6 m20.1 m4.6 m1.4 m7.8 m
Total Debt518,00010.5 m9.2 m6.6 m631,000
Net Debt-27.1 m-9.5 m4.6 m5.1 m-7.2 m
Equity20.8 m7.4 m-11.7 m-23.2 m-15.9 m
Total assets32.7 m25.8 m7.3 m3.7 m13.0 m
Operating cash flow-37.7 m-39.8 m-21.7 m-10.6 m-14.1 m
Investments (capex)7,00003,00000
Free cash-flow-37.7 m-39.8 m-21.7 m-10.6 m-14.1 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-3.07 x
Price / book value-504.94 x
Return on Equity (ROE)168.7 %
Return on Invested Capital (ROIC)-1,855.5 %
Net margin-691.8 %
Debt / equity-7.33 x
Current ratio0.86 x
Interest coverage-17.45 x
Free cash-flow yield-20.9 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.

+

Valuation and competitors

NRx Pharmaceuticals, Inc. compared with its sector on the same exchange and with its main competitors.

Sector median P/E
20.8
healthcare, Nasdaq
Sector over 10 years
28.2
10-year median, range 20.4 to 45.8

Direct competitors

CompanyMarket cap (USD)P/ENet margin
NRx Pharmaceuticals, Inc.103 mn/a-2,336.5 %
Cue Biopharma, Inc. CUE136 mn/a-96.8 %
Outlook Therapeutics, Inc. OTLK106 mn/a-4,416.2 %
Spruce Biosciences, Inc. SPRB134 mn/a0.0 %
Werewolf Therapeutics, Inc. HOWL49.1 mn/a0.0 %
Equillium, Inc. EQ95.7 mn/a0.0 %
Karyopharm Therapeutics Inc. KPTI1.2 mn/a-134.2 %
Century Therapeutics, Inc. IPSC304 mn/a-8.8 %
Senti Biosciences, Inc. SNTI5.0 mn/a-279,263.6 %
Sector median (Nasdaq)20.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering NRx Pharmaceuticals, Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
5 analysts

Breakdown of ratings

strong buy 0buy 5hold 0sell 0strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 6 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.

+

Dividends and earnings

NRx Pharmaceuticals, Inc.: dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Earnings releases

Next release: 16/11/2026. Expected EPS: -0.21.

Factual data: ex-dividend history and earnings calendar, as of 15/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in NRx Pharmaceuticals, Inc.

Free float
86.4 %
share of freely traded shares

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 14/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 04/12/2017
ISIN code
US6294442099
Workforce
2
full-time employees
Chief executive
Jonathan C. Javitt
Next earnings
16/11/2026

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about NRx Pharmaceuticals, Inc.

What is the NRx Pharmaceuticals, Inc. share price?

Latest recorded price: 2.19 USD on 13/11/2026, for a market cap of 94.8 m USD.

When does NRx Pharmaceuticals, Inc. report its next earnings?

The next release is expected on 16/11/2026. EPS expected by analysts: -0.21.

What do analysts say about NRx Pharmaceuticals, Inc.?

Out of 5 analysts: 5 buy or strong buy, 0 hold, 0 sell or strong sell.

Is NRx Pharmaceuticals, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US6294442099).

How many employees does NRx Pharmaceuticals, Inc. have?

2 full-time employees according to the latest published profile.

Who runs NRx Pharmaceuticals, Inc.?

Jonathan C. Javitt is the company's chief executive.

07

Similar stocks